
Contents

Preclinical Models that Illuminate the Bone Metastasis Cascade	1
1 The Clinical Problem of Bone Metastasis	2
2 Spontaneous Carcinogenesis in Animal Models	4
3 Chemical Induction in Cancer Animal Models	5
4 Transplantable Animal Models	5
4.1 Orthotopic Transplantation	6
4.2 Intra- and Supra-Osseous Implantation	8
4.3 Humanized Transplantation Model	9
4.4 Dorsal Skinfold Chamber Model	9
4.5 Systemic Inoculation of Cancer Cells as a Bone Metastasis Model	10
5 Genetically Engineered Mouse Models	11
6 Imaging Modalities	13
6.1 Bioluminescent Imaging	17
6.2 Fluorescent Imaging	19
6.3 Multimodality Imaging	21
6.4 Functional Imaging	22
7 Future Perspectives	24
References	24
 The Role of Bone Microenvironment, Vitamin D and Calcium	 33
1 Bone Premetastatic Niche	34
1.1 Starting From the Primary Tumor Site: The Cancer Stem Cells	35
1.2 The Long Way to the Bone: The Importance of Chemokines . . .	40
1.3 Modification of the Bone Microenvironment: Premetastatic Niche Formation	45
1.4 Osteomimicry	46
1.5 Role of Calcium, Vitamin D and PTH in the Premetastatic Niche	50
References	55

Bisphosphonates: Prevention of Bone Metastases in Breast Cancer . . .	65
1 Introduction	67
2 Bone-Targeted Therapies for Breast Cancer	69
3 Anticancer Effects of Oral Bisphosphonates in Early Breast Cancer	70
3.1 Oral Clodronate	70
3.2 Oral Pamidronate	71
3.3 Anticancer Benefits of Zoledronic Acid	72
3.4 ABCSG-12	73
3.5 ZO-FAST	74
3.6 AZURE	74
3.7 Is There a Subset of Patients More Likely to Benefit From ZOL Anticancer Effects?	76
3.8 Neoadjuvant Therapy	78
3.9 Further Data From Translational Studies in Early Breast Cancer	78
4 Can Bisphosphonates Prevent Cancer?	79
5 Tolerability and Safety of Bisphosphonates as Adjuvant Therapy	82
6 Other Uses of Antiresorptives in Women with Early Breast Cancer	84
7 Conclusions	84
References	85
 Bisphosphonates: Prevention of Bone Metastases in Lung Cancer	 93
1 Introduction	95
2 Incidence of Bone Metastasis in Lung Cancer	95
3 Impact of Bone Metastases: The Rationale for Adequate Treatment	96
4 Diagnosis of Bone Metastases in Lung Cancer	97
5 Treatment of Bone Metastases in Lung Cancer: A Multidisciplinary Affair	99
6 Bisphosphonates in the Treatment of Bone Metastases: The Current Standard of Care	99
6.1 Therapeutic Efficacy of Zoledronic Acid in Lung Cancer: Results From Clinical Trials	100
6.2 Safety Issues and Recommendations for Use	101
6.3 Biochemical Markers of Bone Turnover: Predictors of Clinical Outcome?	101
6.4 Pharmaco-Economic Considerations	102
6.5 Prevention of Bone Metastases: Under Investigation	103
6.6 Evidence for Anti-Tumoral Activity in Lung Cancer?	104
7 Bone Metastasis Therapy in Lung Cancer: What the Future Might Bring	104
7.1 Denosumab	104
7.2 Other Small Molecules	105

8 Conclusion	105
References	106

Bisphosphonates: Prevention of Bone Metastases

in Prostate Cancer	109
1 Introduction	111
1.1 Genitourinary Malignancies: Burden of Disease and Challenges to Bone Health	111
1.2 Hormonal Therapy for Prostate Cancer.	113
2 Anticancer Activity of Antiresorptive Agents in Prostate Cancer.	114
2.1 Preclinical and Translational Data Suggesting Potential Anticancer Activity of Bone-Targeted Agents	114
2.2 Insights From Early Bisphosphonate Trials	115
2.3 Exploratory Analyses From Phase III, Placebo-Controlled Trials of Zoledronic Acid: Benefits in Patients with Elevated Levels of Bone Turnover Markers	115
2.4 Ongoing Clinical Trials Evaluating the Anticancer Potential of Bone-Directed Therapies in the Prostate Cancer Setting	118
3 Anticancer Activity of Bisphosphonates in Other Genitourinary Cancers	119
3.1 Proof-of-Principle Data From Clinical Studies.	119
3.2 Normalization of Bone Markers.	120
4 Conclusions	121
References	121

Targeting Bone in Myeloma	127
1 Bone Disease in Myeloma	128
2 Mechanism of Bone Disease in Myeloma.	128
3 Pathogenesis and Targeting of Bone Disease in Myeloma	130
3.1 What is the Impact of the “Novel Therapies” on Bone Disease	131
3.2 The Anti-Myeloma Effects of Bisphosphonates	132
3.3 Rank/RANKL System	133
3.4 MIP1a	133
3.5 Anti-BAFF-Neutralizing Antibody	133
3.6 Bone Anabolic Agents	134
4 Conclusions	136
References	137

Combinations of Bisphosphonates and Classical Anticancer Drugs:

A Preclinical Perspective	145
1 Molecular Mechanism of Action of BPs.	147
2 BPs-Proposed Mechanisms Behind Their Potential Antitumour Effects	148

2.1	In Vitro Models	148
2.2	In Vivo Models	148
3	BPs in Combination Therapy	149
3.1	In Vitro Studies—The Foundation for BPs as Part of Combination Therapy	150
3.2	In Vivo Studies—Further Evidence of Benefits of BPs in Combination Therapy	153
4	Combination Therapy with BPs—Effects on Tumour Growth in Bone	153
4.1	Summary—Effects on Tumour Growth in Bone	158
5	Combination Therapy with BPs—Effects on Peripheral Tumour Growth	158
5.1	Summary—Effects on Peripheral Tumour Growth	160
6	Sequential Combination Therapy with BPs in the Clinical Setting	161
7	BPs in Combination Therapy—Effects on Normal Cells	162
7.1	Antiangiogenic Effects of BPs as Single Agents	162
7.2	Antiangiogenic Effects of BPs in Combination Therapy	164
8	Conclusions	165
	References	166

Perspectives in the Elderly Patient: Benefits and Limits

	of Bisphosphonates and Denosumab	171
1	Introduction	172
2	Bisphosphonates and Safety Profile: Pharmacokinetic and Pharmacodynamic Interactions	173
3	Preclinical Data on the Antitumoral Efficacy of Bisphosphonates to Prevent Bone Metastases	174
4	The Evolving Role of Zoledronic Acid in Reducing the Risk of Breast Cancer Recurrence in Elderly Patients	174
5	Bisphosphonates and the Risk of Postmenopausal Breast Cancer	176
6	Prospective Trials of Zoledronic Acid in the Adjuvant Setting	176
7	Ongoing Adjuvant Phase III Trials	178
8	Denosumab in the Elderly: Efficacy in Metastatic Disease and New Perspectives in the Adjuvant Setting	180
9	Conclusions	182
	References	183

Denosumab: First Data and Ongoing Studies on the Prevention of Bone Metastases

	187
1	Introduction
2	Denosumab
2.1	Current Indications and Efficacy
2.2	Safety
	188
	189
	189
	190

3	Denosumab: Prevention of Bone Metastases in Prostate Cancer	191
4	Denosumab: Prevention of Bone Metastases in Breast Cancer	192
5	Denosumab: Prevention of Bone Metastases in Other Tumors.	194
	References	195

	Diagnostic and Prognostic Use of Bone Turnover Markers	197
1	Introduction	198
2	Overview on Bone Markers	199
2.1	Bone Formation Markers	199
2.2	Bone Resorption Markers	201
2.3	Osteoclast Regulators: Receptor Activator of Nuclear Factor- κ B Ligand/Osteoprotegerin	202
2.4	Bone Sialoproteins	203
3	Prognostic Use of Bone Markers	204
3.1	Prognostic Use of Bone Markers in Breast Cancer.	208
3.2	Prognostic Use of Bone Markers in Prostate Cancer	209
3.3	Prognostic Use of Bone Markers in Lung Cancer	209
3.4	Prognostic Use of Bone Markers in Multiple Myeloma	210
4	Diagnostic Use of Bone Markers	211
4.1	Diagnostic Use of Bone Markers in Various Tumors	212
4.2	Diagnostic Use of Bone Markers in Breast Cancer	213
4.3	Diagnostic Use of Bone Markers in Prostate Cancer	214
4.4	Diagnostic Use of Bone Markers in Lung Cancer	216
5	Conclusions	217
5.1	Prognostic Use of Bone Turnover Markers	217
5.2	Diagnostic Use of Bone Turnover Markers	218
	References	218

	Osteolytic and Osteoblastic Bone Metastases: Two Extremes of the Same Spectrum?	225
1	Skeletal Responses to Tumor Invasion	226
2	Bone Remodeling in Physiological Conditions	227
3	Osteoblast-Induced Vicious Cycle: Bone Remodeling in Prostate Cancer Bone Metastasis	227
4	Uncoupling of Bone Turnover by Invasion of Prostate Cancer Cells	229
5	Osteoclast-Induced Vicious Cycle: Bone Remodeling in Multiple Myeloma	229
6	Osteolytic and Osteoblastic Bone Metastases: Are They Two Extremes of the Same Spectrum?.	229
	References	231

Prevention of Bone Metastases

Joerger, M.; Gnant, M. (Eds.)

2012, X, 234 p., Hardcover

ISBN: 978-3-642-21891-0